IBIsabelle Vanden Bempt

Isabelle Vanden Bempt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isabelle Vanden Bempt has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Maria Drijkoningen

    From the Departments of Pathology, Obstetrics and Gynecology, Surgery-Senology, and General Medical Oncology and Multidisciplinary Breast Centre, University Hospital Gasthuisberg, and Departments of Human Genetics and Electrical Engineering, Katholieke Universiteit Leuven; and Department of Molecular and Developmental Genetics, Flanders Institute for Biotechnology, Leuven, Belgium

    3 shared publications
  • Christiane De Wolf-Peeters

    From the Departments of Pathology, Obstetrics and Gynecology, Surgery-Senology, and General Medical Oncology and Multidisciplinary Breast Centre, University Hospital Gasthuisberg, and Departments of Human Genetics and Electrical Engineering, Katholieke Universiteit Leuven; and Department of Molecular and Developmental Genetics, Flanders Institute for Biotechnology, Leuven, Belgium

    2 shared publications
  • Ann Smeets

    From the Departments of Pathology, Obstetrics and Gynecology, Surgery-Senology, and General Medical Oncology and Multidisciplinary Breast Centre, University Hospital Gasthuisberg, and Departments of Human Genetics and Electrical Engineering, Katholieke Universiteit Leuven; and Department of Molecular and Developmental Genetics, Flanders Institute for Biotechnology, Leuven, Belgium

    1 shared publication
  • C De Wolf‐Peeters

    Department of Pathology, University Hospital of K.U. Leuven, and Centre for Human Genetics, K.U. Leuven, Leuven, Belgium

    1 shared publication
  • Christiane De Wolf‐Peeters

    Department of Pathology, University Hospital of KU Leuven, Minderbroedersstraat 12, 3000 Leuven, Belgium

    1 shared publication
  • I Wlodarska

    Department of Pathology, University Hospital of K.U. Leuven, and Centre for Human Genetics, K.U. Leuven, Leuven, Belgium

    1 shared publication

Latest Publications

  • Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing

    by Isabelle Vanden Bempt, Peter Van Loo, Maria Drijkoningen, Patrick Neven, Ann Smeets, Marie-Rose Christiaens, Robert Paridaens, Christiane De Wolf-Peeters

    Purpose: Polysomy 17 is frequently found in breast cancer and may complicate the interpretation of HER-2 testing results. We investigated the impact of polysomy 17 on HER-2 testing and studied its clinicopathologic significance in relation to HER2 gene amplification. Patients and Methods: In 226 patients with primary invasive breast carcinoma, HER2 gene and chromosome 17 copy numbers were determined by dual-color fluorescent in situ hybridization (FISH). The interpretation of FISH results was based on either absolute HER2 gene copy number or the ratio HER2/chromosome 17. Results were correlated with HER-2 protein expression on immunohistochemistry (IHC), HER2 mRNA expression by reverse transcriptase polymerase chain reaction (RT-PCR), and with various clinicopathologic parameters. Results: All cases with an equivocal HER-2 result by FISH, either by absolute HER2 copy number (44 of 226 patients; 19.5%) or by the ratio HER2/chromosome 17 (three of 226 patients; 1.3%), displayed polysomy 17. On its own, polysomy 17 was not associated with HER-2 overexpression on IHC or increased HER2 mRNA levels by RT-PCR. Moreover, and in contrast with HER2 gene amplification, polysomy 17 was not associated with high tumor grade, hormone receptor negativity, or reduced disease-free survival. Conclusion: Polysomy 17 affects HER-2 testing in breast cancer and is a major cause of equivocal results by FISH. We show that tumors displaying polysomy 17 in the absence of HER2 gene amplification resemble more HER-2–negative than HER-2–positive tumors. These findings highlight the need for clinical trials to investigative whether polysomy 17 tumors benefit from HER-2–targeted therapy.


  • The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity

    by Isabelle Vanden Bempt, Maria Drijkoningen, Christiane De Wolf-Peeters

    We discuss recent findings on the genotypic alterations associated with HER2-positive breast cancer in an attempt to clarify the clinical heterogeneity observed among these tumors. Molecular genetic analysis supports the distinctive nature of HER2-positive breast cancer, which is primarily driven by HER2 gene amplification. Depending on the amplicon size, a variety of genes can be coamplified and overexpressed together with HER2, some of which may contribute to tumorigenesis; the amplicon size may even predict response to trastuzumab therapy. HER2 gene amplification may further destabilize the tumor genome, facilitating the generation of additional genomic aberrations including aneuploidy. The latter might imply polysomy 17, a phenomenon that should be discriminated from true HER2 gene amplification: polysomy 17 in the absence of HER2 gene amplification is not associated with HER2 overexpression nor with the clinical characteristics of HER2-positive breast cancer. HER2 gene amplification is a complex event: it includes coamplification of other, potentially oncogenic genes and facilitates the generation of additional genomic aberrations. Further studies on these genotypic findings will be helpful to better identify the patients that might benefit from trastuzumab therapy.


  • Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes

    by Isabelle Vanden Bempt, Vera Vanhentenrijk, Maria Drijkoningen, Christiane De Wolf‐Peeters

    In this study, comparative expressed sequence hybridization (CESH) has been used to compare gene expression patterns in three morphologically different breast cancer subtypes: classic‐type invasive lobular carcinoma (ILC), poorly differentiated ERBB2‐negative invasive ductal carcinoma‐not otherwise specified (IDC‐NOS), and poorly differentiated ERBB2‐positive IDC‐NOS. CESH allows global detection of chromosomal regions with differential gene expression in a way similar to that of comparative genomic hybridization (CGH). Eight cases of each breast cancer subtype were included in the study. For each subtype, two pools of four cases each were constructed. CESH was used to compare both pools within the same morphological subtype, followed by a comparison of pools belonging to different subtypes. This revealed three chromosomal regions that were differentially expressed in ductal and lobular carcinomas, including relative overexpression at 8q13–q23 and 16q22, and relative underexpression at 8p21–p22. In addition, an expression signature characterized by relative overexpression at 3q24–q26.3, 14q23–31, 17q12, and 20q12–13 was identified for ERBB2‐positive IDC‐NOS. In summary, CESH analysis highlights chromosomal regions of differential gene expression that are associated with morphologically defined breast cancer subtypes and suggests that regions on chromosome 8 are of interest in the discrimination between ductal and lobular carcinomas. In addition, using CESH, it was possible to identify an ERBB2 expression signature, comprising four chromosomal regions with potential significance in the aggressive behaviour of ERBB2‐positive IDC‐NOS. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Real‐time reverse transcription‐PCR and fluorescence in‐situ hybridization are complementary to understand the mechanisms involved in HER‐2/neu overexpression in human breast carcinomas

    by I Vanden Bempt, V Vanhentenrijk, M Drijkoningen, I Wlodarska, P Vandenberghe, C De Wolf‐Peeters

    To evaluate the HER-2/neu status at the mRNA and DNA level of breast carcinomas and to compare it with HER-2/neu receptor overexpression by immunohistochemistry (IHC). In 32 invasive breast carcinomas, frozen tissue was available for real-time detection of HER-2/neu mRNA levels by reverse transcription-polymerase chain reaction (RT-PCR). Corresponding paraffin sections were examined by IHC and fluorescence in-situ hybridization (FISH). Thereby, different IHC and FISH procedures were compared. Using microwave epitope retrieval, all 32 cases scored 3+ on IHC, whereas only 28 out of 32 cases scored IHC 3+ using water bath epitope retrieval. All of these 28 cases showed increased levels of HER-2/neu mRNA. Dual-colour FISH analysis showed corresponding gene amplification in all 28 cases, with two cases showing a peculiar amplification pattern. In the remaining four cases, scoring IHC 2+ using water bath epitope retrieval, mRNA levels were not elevated. Three cases did not have gene amplification and one case showed low-level HER-2/neu gene amplification. All four carcinomas showed chromosome 17 polysomy. Real-time RT-PCR is accurate in selecting breast carcinoma cases scoring 3+ by IHC with high-level gene amplification. Results obtained by dual-colour FISH suggest that mechanisms leading to HER-2/neu receptor overexpression may be different between carcinomas scoring 2+ and 3+ on IHC, with polysomy 17 found in the former and gene amplification in the latter.